Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  A. Krasnitz,et al.  Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. , 2009, Cancer cell.

[3]  Corbin E. Meacham,et al.  In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression , 2009, Nature Genetics.

[4]  Fengzhu Sun,et al.  A network-based integrative approach to prioritize reliable hits from multiple genome-wide RNAi screens in Drosophila , 2009, BMC Genomics.

[5]  A. Krasnitz,et al.  An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.

[6]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[7]  Stephen J. Elledge,et al.  Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.

[8]  S. Rha,et al.  Whole genome analysis for liver metastasis gene signatures in colorectal cancer , 2007, International journal of cancer.

[9]  R. Weinberg,et al.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. , 2007, Cancer Cell.

[10]  T. Yeatman,et al.  Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer , 2007, Genome Biology.

[11]  Chi-Ying F. Huang,et al.  Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme , 2007, BMC Genomics.

[12]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[13]  G. Turashvili,et al.  Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis , 2007, BMC Cancer.

[14]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[15]  Nir Hacohen,et al.  Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.

[16]  C. Glass,et al.  Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression. , 2006, Cancer research.

[17]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[18]  Deon Venter,et al.  The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Chin,et al.  A Genetic Screen for Candidate Tumor Suppressors Identifies REST , 2005, Cell.

[20]  David Botstein,et al.  Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. , 2004, Molecular biology of the cell.

[21]  A. Wynshaw-Boris,et al.  Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis , 2003, The EMBO journal.

[22]  C. Watson,et al.  A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland , 2003, Development.

[23]  Ke Gong,et al.  Solution Structure of the C-terminal Domain of the Ciliary Neurotrophic Factor (CNTF) Receptor and Ligand Free Associations among Components of the CNTF Receptor Complex* , 2003, Journal of Biological Chemistry.

[24]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[26]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[28]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[29]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[30]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[31]  H. J. Evans,et al.  Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. , 1990, Oncogene.

[32]  Raphael A Nemenoff,et al.  Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model , 2010 .

[33]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.